null

null

null

null

null

null

null

null

null

Near-zero debt; cash-funded clinical-stage biotech with no material long-term debt; 20% rate rise has negligible P&L impact

Minimal; company holds cash/equivalents, not debt instruments; rising rates marginally improve interest income on cash reserves

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API synthesis dependency on contract manufacturers in China and India; geopolitical disruption in either market could delay clinical supply

No international revenue; USD-denominated operations only; sovereign currency devaluation exposure is effectively zero

Entirely US-based operations and clinical trials; no material foreign revenue exposure to currency devaluation risk

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Likely high dependency on single CRO and CMO partners for clinical execution; substitution possible but costly and time-consuming

Clinical-stage pharmaceutical R&D; no commercial product; revenue from licensing or partnerships, not cloud-dependent SaaS

Potential future royalty/licensing model upon drug approval; cloud termination would disrupt data management but not core IP

Low API coupling risk; company relies on internal research platforms and standard CRO data systems, not proprietary third-party APIs

Low Howey risk; equity shares fund drug development with returns tied to R&D outcomes, not profit-sharing arrangements resembling securities contracts

Very High

Moderate; clinical trial patient data subject to HIPAA primarily; GDPR exposure minimal given US-only trials; CCPA applicable to employee data

Negligible; pre-commercial stage with no market share; no pricing power or exclusionary conduct risk in relevant therapeutic markets

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

100% transactional/milestone-based; no recurring subscription revenue; dependent on partnership milestones and potential future royalties

Licensing/partnership milestones and future royalties on ACC/NASH drug candidates, primarily TVB-2640 (denifanstat)

No commercial pricing yet; future pricing will depend on NASH/liver disease market comparables (~$15K–$30K/year patient cost range)

Unproven; if approved, orphan-like positioning in NASH could support premium pricing, but competitive pipeline limits long-term power

Royalty/licensing model targets 80–90% gross margin post-approval; current R&D spend yields negative gross margin

No free-rider risk; proprietary FAS inhibitor IP with patent protection; no open-access or freemium leakage model exists

Headcount-sublinear at scale; drug royalties require minimal incremental staff; current ~30-person team is R&D-heavy and lean

Near-zero marginal cost post-approval in royalty model; doubling revenue via licensing requires no proportional headcount increase

null

At 10x scale, CAC irrelevant; value driver is FDA approval probability and partner deal terms, not traditional customer acquisition

No network effects; pharmaceutical IP moat is patent-based, not network-driven; durability tied to exclusivity period (~2028–2032)

AI displacement risk low in near term; FAS inhibitor mechanism is chemistry-based; AI could accelerate discovery but not replace existing IP

Moderate-low; clinical-stage biotech funding is risk-on capital; recession tightens biotech venture/partnership capital availability significantly

Large pharma/biotech licensing partners (e.g., potential NASH-focused acquirers); high concentration risk with few potential counterparties

Academic and government grant bodies providing non-dilutive funding; secondary but reduces burn rate dependency on equity markets

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Minimal capex; capital allocated almost entirely to clinical trial opex (Phase 2/3 studies); no legacy infrastructure reallocation needed

0001400118

SGMT